170 related articles for article (PubMed ID: 34956490)
1. Prognostic significance of tumor-infiltrating lymphocytes in premenopausal, luminal breast cancer treated with adjuvant endocrine therapy.
Zhang J; Abubakar M; Yuan P; Koka H; Guo L; Li X; Yang XR; Ying J; Lyu N
Am J Transl Res; 2021; 13(11):12750-12762. PubMed ID: 34956490
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
Yang X; Rao J; Yang W; Shui R
Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
[TBL] [Abstract][Full Text] [Related]
3. Association between CD8+ Tumor Infiltrating Lymphocytes and the Clinical Outcome of Patients with Operable Breast Cancer Treated with Adjuvant Dose-Dense Chemotherapy-A 10 Year Follow-Up Report of a Hellenic Cooperative Oncology Group Observational Study.
Spathas N; Goussia AC; Koliou GA; Gogas H; Zagouri F; Batistatou A; Charchanti AV; Papoudou-Bai A; Bobos M; Chrisafi S; Chatzopoulos K; Kostopoulos I; Koletsa T; Arapantoni P; Pectasides D; Galani E; Koutras A; Zarkavelis G; Saloustros E; Bafaloukos D; Karanikiotis C; Bompolaki I; Aravantinos G; Psyrri A; Razis E; Koumarianou A; Res E; Linardou H; Fountzilas G
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428728
[TBL] [Abstract][Full Text] [Related]
4. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer.
Matsumoto H; Thike AA; Li H; Yeong J; Koo SL; Dent RA; Tan PH; Iqbal J
Breast Cancer Res Treat; 2016 Apr; 156(2):237-47. PubMed ID: 26960711
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.
Fujimoto Y; Watanabe T; Hida AI; Higuchi T; Miyagawa Y; Ozawa H; Bun A; Fukui R; Sata A; Imamura M; Hirota S; Miyoshi Y
Breast Cancer; 2019 Nov; 26(6):738-747. PubMed ID: 31098866
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of tumour-infiltrating lymphocytes, programmed cell death protein-1 and programmed cell death ligand-1 in Stage I-III triple-negative breast cancer.
Sun GY; Zhang J; Wang BZ; Jing H; Fang H; Tang Y; Song YW; Jin J; Liu YP; Tang Y; Qi SN; Chen B; Lu NN; Li N; Li YX; Ying JM; Wang SL
Br J Cancer; 2023 Jun; 128(11):2044-2053. PubMed ID: 36966236
[TBL] [Abstract][Full Text] [Related]
7. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral, rather than stromal, CD8+ T cells could be a potential negative prognostic marker in invasive breast cancer patients.
Catacchio I; Silvestris N; Scarpi E; Schirosi L; Scattone A; Mangia A
Transl Oncol; 2019 Mar; 12(3):585-595. PubMed ID: 30682679
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers.
Tian T; Ruan M; Yang W; Shui R
Oncotarget; 2016 Jul; 7(28):44395-44405. PubMed ID: 27323808
[TBL] [Abstract][Full Text] [Related]
10. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
Gao ZH; Li CX; Liu M; Jiang JY
BMC Cancer; 2020 Nov; 20(1):1150. PubMed ID: 33238978
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.
Dieci MV; Mathieu MC; Guarneri V; Conte P; Delaloge S; Andre F; Goubar A
Ann Oncol; 2015 Aug; 26(8):1698-704. PubMed ID: 25995301
[TBL] [Abstract][Full Text] [Related]
12. Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes.
Dimitrakopoulos FI; Goussia A; Koliou GA; Dadouli K; Batistatou A; Kourea HP; Bobos M; Arapantoni-Dadioti P; Tzaida O; Koletsa T; Chrisafi S; Sotiropoulou M; Papoudou-Bai A; Nicolaou I; Charchanti A; Mauri D; Aravantinos G; Binas I; Res E; Psyrri A; Pectasides D; Bafaloukos D; Koumarianou A; Bompolaki I; Rigakos G; Karanikiotis C; Koutras A; Zagouri F; Gogas H; Fountzilas G
Breast; 2024 Feb; 73():103668. PubMed ID: 38176305
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer.
Sønderstrup IMH; Jensen MB; Ejlertsen B; Eriksen JO; Gerdes AM; Kruse TA; Larsen MJ; Thomassen M; Laenkholm AV
Acta Oncol; 2019 Mar; 58(3):363-370. PubMed ID: 30614364
[TBL] [Abstract][Full Text] [Related]
14. Predictive and prognostic significance of CD8
Al-Saleh K; Abd El-Aziz N; Ali A; Abozeed W; Abd El-Warith A; Ibraheem A; Ansari J; Al-Rikabi A; Husain S; Nabholtz JM
Oncol Lett; 2017 Jul; 14(1):337-344. PubMed ID: 28693173
[TBL] [Abstract][Full Text] [Related]
15. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.
Loi S; Drubay D; Adams S; Pruneri G; Francis PA; Lacroix-Triki M; Joensuu H; Dieci MV; Badve S; Demaria S; Gray R; Munzone E; Lemonnier J; Sotiriou C; Piccart MJ; Kellokumpu-Lehtinen PL; Vingiani A; Gray K; Andre F; Denkert C; Salgado R; Michiels S
J Clin Oncol; 2019 Mar; 37(7):559-569. PubMed ID: 30650045
[TBL] [Abstract][Full Text] [Related]
16. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
[TBL] [Abstract][Full Text] [Related]
17. Stromal or intraepithelial tumor-infiltrating lymphocytes: which one has more prognostic significance in cervical cancer?
Gultekin M; Beduk Esen CS; Ates Ozdemir D; Yildirim S; Yuce D; Usubutun A; Yildiz F
Arch Gynecol Obstet; 2023 Mar; 307(3):969-980. PubMed ID: 35840843
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer.
Jang N; Kwon HJ; Park MH; Kang SH; Bae YK
Ann Surg Oncol; 2018 Apr; 25(4):937-946. PubMed ID: 29330719
[TBL] [Abstract][Full Text] [Related]
19. Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
Kolberg-Liedtke C; Gluz O; Heinisch F; Feuerhake F; Kreipe H; Clemens M; Nuding B; Malter W; Reimer T; Wuerstlein R; Graeser M; Shak S; Nitz U; Kates R; Christgen M; Harbeck N
Breast Cancer Res; 2020 May; 22(1):47. PubMed ID: 32408905
[TBL] [Abstract][Full Text] [Related]
20. Tumor-infiltrating lymphocytes provides recent survival information for early-stage HER2-low-positive breast cancer: a large cohort retrospective study.
Sun T; Wang T; Li X; Wang H; Mao Y
Front Oncol; 2023; 13():1148228. PubMed ID: 37409261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]